Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

by · The Markets Daily

Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 1,840,000 shares, a growth of 1,610.0% from the November 30th total of 107,600 shares. Approximately 67.7% of the shares of the company are sold short. Based on an average daily volume of 1,220,000 shares, the short-interest ratio is currently 1.5 days.

Palisade Bio Trading Up 4.7 %

Palisade Bio stock traded up $0.08 during mid-day trading on Thursday, hitting $1.79. The stock had a trading volume of 86,772 shares, compared to its average volume of 663,681. Palisade Bio has a one year low of $1.38 and a one year high of $22.35. The firm has a market capitalization of $2.71 million, a P/E ratio of -0.13 and a beta of 1.39. The firm’s 50 day moving average is $2.49 and its 200 day moving average is $3.42.

Palisade Bio (NASDAQ:PALI – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.35) by $1.03. As a group, equities research analysts forecast that Palisade Bio will post -12.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PALI. Maxim Group reduced their price target on Palisade Bio from $22.50 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Brookline Capital Management initiated coverage on shares of Palisade Bio in a research note on Wednesday, November 20th. They set a “buy” rating and a $38.00 target price on the stock.

Get Our Latest Stock Analysis on Palisade Bio

About Palisade Bio

(Get Free Report)

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.

Featured Stories